Reduction in the risk of major adverse cardiovascular events with the BET protein inhibitor apabetalone in patients with recent acute coronary syndrome, type 2 diabetes, and moderate to high likelihood of non-alcoholic fatty liver disease

• Main Authors: Peter P. Toth (Author), Gregory G. Schwartz (Author), Stephen J. Nicholls (Author), Aziz Khan (Author), Michael Szarek (Author), Henry N. Ginsberg (Author), Jan O. Johansson (Author), Kamyar Kalantar-Zadeh (Author), Ewelina Kulikowski (Author), Ken Lebioda (Author), Norman C.W. Wong (Author), Michael Sweeney (Author), Kausik K. Ray (Author)
• Format: Book
• Published: Elsevier, 2022-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: Nonalcoholic fatty liver disease (NAFLD) is common among patients with type 2 diabetes mellitus (T2DM) and is associated with increased risk for coronary atherosclerosis and acute cardiovascular (CV) events. We employed the validated, non-invasive Angulo NAFLD fibrosis score (FS) in an i...